Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2600127664Phase 4Not yet recruiting
Phase 4, randomised trial of dexmedetomidine, esketamine, sufentanil and remifentanil in colorectal cancer (CRC) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Quality of Recovery (QoR‑15) score at 24 hours postoperatively. Planned start Jul 2026; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2600127664.